Lamotrigine ' s chemical structure
Find information on thousands of medical conditions and prescription drugs.

Lamotrigine

Lamotrigine (marketed as Lamictal by GlaxoSmithKline) is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the only anticonvulsant mood stabilizer that treats the depressive as well as the manic phases of bipolar disorders, and it is the first medication since Lithium granted FDA-approval for the maintenance treatment of bipolar I. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. It is a Na+ channel blocker, and is inactivated by hepatic glucuronidation.

U.S. FDA approval history

  • December 1994 - for use as adjunctive treatment for partial seizures with or without secondary generalization in adult patients (16 years of age and older).
  • August 1998 - for use as adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients, new dosage form: chewable dispersible tablets.
  • December 1998 - for use as monotherapy for treatment of partial seizures in adult patients when converting from a single enzyme-inducing anti-epileptic drug (EIAED).
  • January 2003 - for use as adjunctive therapy for partial seizures in pediatric patients as young as 2 years of age.
  • June 2003 - for the maintenance treatment of adults with Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy. Additionally, the FDA has noted that findings for Lamictal maintenance treatment were more robust in bipolar depression.
  • January 2004 - for use as monotherapy for treatment of partial seizures in adult patients when converting from the anti-epileptic drug valproate (including valproic acid (Depakene) and divalproex sodium (Depakote)).

Indications & Usage

The FDA approved lamotrigine (Lamictal) for the treatment of epilepsy in 1994, and bipolar I disorder in 2003 (

Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy. Typically developing before 4 years of age, LGS is associated with developmental delays. There is no cure, treatment is often complicated, and complete recovery is rare. Symptoms include the atonic seizure (also known as a "drop attack"), during which brief loss of muscle tone and consciousness cause abrupt falls. Lamotrigine significantly reduces the frequency of LGS seizures, and is one of two medications known to decrease the severity of drop attacks (French et al., 2004). Combination with valproate is common, but this increases the risk of lamotrigine-induced rash, and necessitates reduced dosing due to the interaction of these drugs (Pellock, 1999).

Lamotrigine (Lamictal) is the first FDA-approved therapy since Lithium for maintenance treatment of bipolar I disorder (GlaxoSmithKline, 2003). These are the only true "mood stabilizers" in that they possess antidepressant as well as antimanic properties, and research has shown that of the two, lamotrigine is the more effective treatment for bipolar depression. Traditional anticonvulsant drugs are primarily antimanics. Lamotrigine treats depression without triggering mania, hypomania, mixed states, or rapid-cycling, and the 2002 American Psychiatric Association guidelines recommended lamotrigine as a first-line treatment for acute depression in bipolar disorder as well as a maintenance therapy, however lamotrigine is not indicated "on label" for treatment of acute symptoms.

Read more at Wikipedia.org


[List your site here Free!]


Retigabine: A novel anticonvulsant drug
From Indian Journal of Pharmacology, 9/1/05 by I. Anand

Byline: I. Anand, J. Shah, S. Patel, C. Patel

Epilepsy is a neurological disorder characterized by excessive electrical discharge in brain, which causes seizures. The therapeutic strategy in countering epilepsy involves reducing neuronal excitability through different mechanistic pathways. Most therapeutics currently used in the treatment of epilepsy is either directed towards blocking voltage-gated sodium and calcium channels or potentiating gamma amino butyric acid (GABA)-mediated neurotransmission, with little focus on voltage-gated potassium ion channels, despite these channels having a major role in the control of all aspects of neuronal excitability. It is reported that functional impairment of potassium ion channels, either by mutation or inhibition, results in epilepsy.[1]

Retigabine (D23129), N-[2-amino-4-(4-fluorobenzylamino) phenyl] carbamic acid ethyl ester is a close structural analog of the centrally acting analgesic flupitrine. It is a purple colored compound with a molecular weight of 376.23, calc log P of 2.0 and a pKa of 10.8 (calculated as free base). Retigabine dihydrochloride appears to be hygroscopic, as medium to long-term storage at 18 [degrees]C (with presumed freeze-thawing) produces significant amounts of ring-closed product 5-(4-fluoro-benzylamino)-1,3-dihydro-benzimidazol-2-one and small amounts of uncharacterized oxidized products. Therefore, it is preferably stored as the free base, isolated from light.[2]

Retigabine has a novel mechanism of action that involves opening of neuronal Kv7.2-7.5 (formerly KCNQ2-5) voltage activated K+ channels. These channels (primarily Kv7.2/7.3) enable generation of the M-current, a sub-threshold K+ current that serves to stabilize the membrane potential and control neuronal excitability.[3] In addition to acting on potassium ion channels, retigabine also affects GABA neurotransmission in the GABAA receptor, which is a key inhibitory receptor in the central nervous system and is implicated in epilepsy.[4] Malfunctioning of the GABAA receptor leads to hyperexcitability in the brain, which causes seizures, making this receptor an important target for antiepileptic therapeutics. Apart from increasing the concentration of GABA in the brain (by either enhancing GABA synthesis or blocking GABA metabolism), retigabine allosterically potentiates GABA-induced current in rat cortical neurons in a concentration-dependent manner.[4] Numerous studies have demonstrated that retigabine is effective in a broad spectrum of in vivo epilepsy and seizure models. Retigabine was shown to be active (ED<sub>50</sub> range = 4.0-18.6 mg/kg, i.p.) against electrically induced seizures and against chemical seizures induced by pentylenetetrazole, picrotoxin and NMDA in mice.[5] Retigabine was also reported to attenuate sound-induced seizures in DBA/2 mice, a model of genetic epilepsy.[5] In the full amygdala-kindling model of complex partial seizures in rats, retigabine, at 0.01 to 5 mg/kg, i.p., has been reported to dose dependently increase the threshold current for induction of after discharges. Following stimulation with the after discharge threshold current, retigabine (5 mg/kg, i.p.) also reduced other seizure measures including seizure severity, seizure duration, total duration of behavioral changes and of changes after discharge.[6]

A number of recent studies have reported that retigabine can relieve pain-like behaviors in animal models of neuropathic pain. [7],[8],[9] Some animal experiments using mouse have shown that retigabine (1-10 mg/kg, i.p.) can dose dependently reduce anxiety-like behaviour.[10], [11]

Retigabine is rapidly absorbed and distributed, with an oral bioavailability of 60% and a high volume of distribution of approximately 6.2 L/kg.[12] Plasma protein binding of the drug is approximately 80%. The relatively high systemic bioavailability after oral administration suggests that retigabine is resistant to first-pass metabolism, a finding confirmed in multiple species. Retigabine is metabolized exclusively via phase II hepatic glucurodination and acetylation.[13], [14] In clinical multiple oral-dosing studies, it has been demonstrated that retigabine reaches steady state on the third day of dosing.[15] Relative exposure appears to be dependent upon the dose administered, but does not exhibit accumulation. Plasma retigabine rises following zero-order kinetics, and decays following first-order process. Gender differences in exposure have been noted with female subjects exhibiting higher plasma concentrations of the drug after single oral administration (200 mg) than male subjects.[12] Excretion of retigabine appears to be predominantly renal. In humans, 84% of an administered dose of [[14]C] retigabine is recovered in urine either as unchanged parent drug, N-glucuronides of retigabine, or in acetylated form.[16]

After oral administration in rats retigabine shows a therapeutic index of 28.8, which compares favorably with that reported for other antiepileptics, such as carbamazepine.[17] Only limited published data are available for retigabine in humans. Human studies suggest that retigabine is not associated with tolerance, dependence, or withdrawal liability. Tolerability was reported to be good when retigabine was titrated-up to its effective dose range (600-1200 mg/day).[16] In fixed-dose healthy volunteer studies, 500 mg appeared to be the maximum tolerated dose (MTD), although it is known that the MTD in epileptic patients is considerably higher. In up-titrated volunteers, 700 mg per day retigabine was tolerated without any dose-limiting adverse events.[15] Adverse events for both fixed-dose and up-titrated dosing of retigabine were found to be similar and included mild dizziness, headache, asthenia, nausea, and somnolence. At doses greater than the MTD, retigabine was associated with chills, pain, symptomatic hypotension, myalgia, sweating and vomiting.[15]

Retigabine has successfully completed Phase II clinical trial with the FDA for the treatment of epilepsy.[18]

As compared to other antiepileptic agents, retigabine is unique in that it selectively activates potassium ion channels Kv 7.2-Kv7.5 and not cardiac Kv 7.1, thereby avoiding cardiac side effects.[19] The antiepileptics, as a drug class, are routinely used in the treatment of a number of disease states in addition to epilepsy. Retigabine is highly efficacious in a broad-spectrum of in vivo epilepsy and seizure models. A comparison of antiepileptic form activity of retigabine with that of conventional anticonvulsants in in vitro models suggests that retigabine is especially likely to be useful in the treatment of pharmacoresistant epilepsy. Retigabine clearly attenuates pain-like behaviors in various animal models of neuropathic pain; it may also prove to be useful in treatment of clinical anxiety disorders. Clinical data obtained thus far indicate that retigabine is well tolerated in humans when titrated up to its therapeutic dose range. No tolerance, drug dependence, or withdrawal liability has been reported. Thus, retigabine may prove to be useful in the treatment of a diverse range of disease states in which neuronal hyperexcitability is a common underlying factor.

References

1. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Clin Pharmacol 1997;336:243-249.

2. Meisel P, Landgraf K-F, Schafer J, Thiel W, Rischer W, Olbrich A, et al . US Patent (5,914,425) 1999.

3. Wuttke T, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant Retigabine favors voltage-dependent opening of Kv7.2(KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-17.

4. Rundfelt C, Netzer R. Investigations into mechanism of action of new anticonvulsant. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000;50:1063-70.

5. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Emanuele E, et al . D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-23.

6. Tober C, Rostock A, Rundfeldt C, Bartsh R. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-9.

7. Blackburn-Munro G, Skaning Jensen B. The anticonvulsant retigabine attenuates nociceptive behaviours in animal models of persistent and neuropathic pain. Eur J Pharmacol 2003;460:109-16.

8. Dost R, Rostock A, Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedeberds Arch Pharmacol 2004;369:382-90.

9. Nielsen AN, Mathiesen C, Blackburn-Munro G. Pharmacological characterization of acid-induced muscle allodynia in rats. Eur J Pharmacol 2004;487:93-103.

10. Njung'e K, Handley SL. Evaluation of marble-burying behaviour as a model of anxiety. Pharmacol Biochem Behav 1991;38:63-7.

11. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological characterization of the elevated 'zero-maze' as an animal model of anxiety. Psychopharmacology 1994;116:56-64.

12. Hermann R, Ferron GM, Erb K, Knebel N, Ruus P, Paul J, et al . Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003;73:61-70.

13. Hempel R, Schupke H, McNeilly PJ, Heinecke K, Kronbach C, Grunwald C, et al . Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999;27:613-22.

14. McNrilly PJ, Torchin CD, Anderson LW, Kapetanovic IM, Kupferberg JH, Strong JM. In vitro glucuronidation of D-2319, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997;27:431-41.

15. Friedel HA, Fitton A. Flupitrine. A review of its pharmacological properties and therapeutic efficacy in pain states. Drugs 1993;45:548-69.

16. Hermann R, Knebel NG, Neibch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol 2003;58:795-802.

17. De Sarro G, Di Paola ED, Conte G, Pasculli MP, De Sarro A. Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naunyn Schmiedebergs Arch Pharmacol 2001;363:330-6.

18. Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Gesty J, et al . Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42:175-182.

19. Wuttke T, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of Kv7.2(KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-17.

COPYRIGHT 2005 Medknow Publications
COPYRIGHT 2005 Gale Group

Return to Lamotrigine
Home Contact Resources Exchange Links ebay